Psychological Medicine

cambridge.org/psm

Original Article

†The members of the Italian Network for Research on Psychoses are listed in the Appendix.

Cite this article: Mucci A *et al* (2018). Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. *Psychological Medicine* **48**, 1359–1366. https://doi.org/10.1017/ S0033291717002902

Received: 8 March 2017 Revised: 7 August 2017 Accepted: 6 September 2017 First published online: 11 October 2017

Key words:

Attention; MCCB Italian standardization; reasoning and problem solving; social cognition; verbal learning; working memory

Author for correspondence: A. Mucci, E-mail: armida.mucci@gmail.com

© Cambridge University Press 2017



Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives

A. Mucci¹, S. Galderisi¹, M. F. Green^{2,3}, K. Nuechterlein^{2,4}, P. Rucci⁵, D. Gibertoni⁵,
A. Rossi⁶, P. Rocca⁷, A. Bertolino⁸, P. Bucci¹, G. Hellemann², M. Spisto¹,
D. Palumbo¹, E. Aguglia⁹, G. Amodeo¹⁰, M. Amore¹¹, A. Bellomo¹², R. Brugnoli¹³,
B. Carpiniello¹⁴, L. Dell'Osso¹⁵, F. Di Fabio¹⁶, M. di Giannantonio¹⁷, G. Di
Lorenzo¹⁸, C. Marchesi¹⁹, P. Monteleone²⁰, C. Montemagni⁷, L. Oldani²¹,
R. Romano⁸, R. Roncone²², P. Stratta⁶, E. Tenconi²³, A. Vita²⁴, P. Zeppegno²⁵,
M. Maj¹ and Italian Network for Research on Psychoses[†]

¹Department of Psychiatry, Campania University "Luigi Vanvitelli", Naples, Italy; ²Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA; ³Department of Veterans Affairs, Desert Pacific Mental Illness Research, Education, and Clinical Center, Long Beach, CA, USA; ⁴Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA; ⁵Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; ⁶Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry, University of L'Aquila, L'Aquila, Italy; ⁷Department of Neuroscience, Section of Psychiatry, University of Turin, Turin, Italy; ⁸Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy; ⁹Department of Clinical and Molecular Biomedicine, Psychiatry Unit, University of Catania, Catania, Italy; ¹⁰Department of Molecular Medicine and Clinical Department of Mental Health, University of Siena, Siena, Italy; ¹¹Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, Section of Psychiatry, University of Genoa, Genoa, Italy; ¹²Department of Medical Sciences, Psychiatry Unit, University of Foggia, Foggia, Italy; ¹³Department of Neurosciences, Mental Health and Sensory Organs, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy; ¹⁴Department of Public Health, Clinical and Molecular Medicine, Section of Psychiatry, University of Cagliari, Cagliari, Italy; ¹⁵Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy; ¹⁶Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy; ¹⁷Department of Neuroscience and Imaging, Chair of Psychiatry, G. d'Annunzio University, Chieti, Italy; ¹⁸Department of Systems Medicine, Chair of Psychiatry, Tor Vergata University of Rome, Rome, Italy; ¹⁹Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy; ²⁰Department of Medicine and Surgery, Chair of Psychiatry, University of Salerno, Salerno, Italy; ²¹Department of Psychiatry, University of Milan, Milan, Italy; ²²Department of Life, Health and Environmental Sciences, Unit of Psychiatry, University of L'Aquila, L'Aquila, Italy; ²³Psychiatric Clinic, Department of Neurosciences, University of Padua, Padua, Italy; ²⁴Department of Mental Health, Psychiatric Unit, School of Medicine, University of Brescia, Spedali Civili Hospital, Brescia, Italy and ²⁵Department of Translational Medicine, Psychiatric Unit, University of Eastern Piedmont, Novara, Italy

Abstract

Background. The increased use of the MATRICS Consensus Cognitive Battery (MCCB) to investigate cognitive dysfunctions in schizophrenia fostered interest in its sensitivity in the context of family studies. As various measures of the same cognitive domains may have different power to distinguish between unaffected relatives of patients and controls, the relative sensitivity of MCCB tests for relative-control differences has to be established. We compared MCCB scores of 852 outpatients with schizophrenia (SCZ) with those of 342 unaffected relatives (REL) and a normative Italian sample of 774 healthy subjects (HCS). We examined familial aggregation of cognitive impairment by investigating within-family prediction of MCCB scores based on probands' scores.

Methods. Multivariate analysis of variance was used to analyze group differences in adjusted MCCB scores. Weighted least-squares analysis was used to investigate whether probands' MCCB scores predicted REL neurocognitive performance.

Results. SCZ were significantly impaired on all MCCB domains. REL had intermediate scores between SCZ and HCS, showing a similar pattern of impairment, except for social cognition. Proband's scores significantly predicted REL MCCB scores on all domains except for visual learning.

Conclusions. In a large sample of stable patients with schizophrenia, living in the community, and in their unaffected relatives, MCCB demonstrated sensitivity to cognitive deficits in both groups. Our findings of significant within-family prediction of MCCB scores might reflect disease-related genetic or environmental factors.

Introduction

Cognitive deficits represent core features of schizophrenia, observable in all stages of the disorder and before its onset, irrespective of the severity of symptoms (Heinrichs & Zakzanis, 1998; Green *et al.* 2000, 2004; Galderisi *et al.* 2002, 2009, 2013; Keefe *et al.* 2011; Kern *et al.* 2011; Bora *et al.* 2014; Dickerson *et al.* 2014). They are strong predictors of functional outcome (Green *et al.* 2000; Bowie *et al.* 2006; Harvey & Strassnig, 2012; Galderisi *et al.* 2014) and have a greater impact on social functioning than positive and negative symptoms (Leifker *et al.* 2009; Kurtz *et al.* 2010; Harvey & Strassnig, 2012; Galderisi *et al.* 2014, 2016).

Deficits in social cognition (i.e. emotion processing and management, theory of mind, social perception and attributional style) (Green *et al.* 2008) were reported in all phases of the disorder and in the prodromal period (Kohler *et al.* 2010; Fett *et al.* 2011; Green *et al.* 2012*a*; Gallagher & Varga, 2015; Green, 2016). These deficits are only partly predicted by other cognitive deficits, and were found to mediate the impact of the latter on functional outcome and to explain a unique proportion of functional outcome variance (Couture *et al.* 2011; Fett *et al.* 2011; Mancuso *et al.* 2011; Schmidt *et al.* 2011; Green *et al.* 2012*b*; Galderisi *et al.* 2014; Green, 2016).

The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB, Kern *et al.* 2008; Nuechterlein *et al.* 2008) was developed to provide a comprehensive assessment of cognitive functioning in patients with schizophrenia or schizoaffective disorder for the purposes of conducting clinical trials (Nuechterlein *et al.* 2008). Previous findings showed that the MCCB is a sensitive instrument to detect cognitive impairments in patients with schizophrenia (Keefe *et al.* 2011; Kern *et al.* 2011; Shamsi *et al.* 2011; Lystad *et al.* 2014; McCleery *et al.* 2014) and changes following either pharmacological or cognitive remediation interventions (for a review, see Green *et al.* 2014).

Cognitive dysfunction has also been found in non-psychotic first-degree relatives of schizophrenia patients, with a severity of impairment intermediate between patients and controls (Brahmbhatt et al. 2006; Snitz et al. 2006; Gur et al. 2007; Chen et al. 2009; de Achával et al. 2010; Bora & Pantelis, 2013), suggesting that cognitive dysfunction can potentially be used as a marker of genetic vulnerability for psychosis (Grove et al. 1991; Chen et al. 1998; Sitskoorn et al. 2004; Gur et al. 2007; Calkins et al. 2010, 2013; Seidman et al. 2015). Attention, verbal memory, and executive control were generally found more impaired than other functions (Sitskoorn et al. 2004; Snitz et al. 2006; Gur et al. 2007; Seidman et al. 2015), but effects were influenced by the included tests or measures and by a number of other factors, such as the type of relationship with the proband (parent/sibling/ offspring), matching between relatives and controls, and the presence of an axis I (other than schizophrenia) or II diagnosis in relatives (Snitz et al. 2006; Gur et al. 2007; Calkins et al. 2013; Gur & Gur, 2016). Social cognition deficits were also found in relatives of patients with schizophrenia, although with some inconsistency in the literature as to what specific deficit is involved (Fett et al. 2011; Bora & Pantelis, 2013; Lavoie et al. 2013).

The MCCB includes some of the tests and measures consistently found to differ between relatives and controls (Gur *et al.* 2007; Calkins *et al.* 2013; Seidman *et al.* 2015), but also other measures for which the sensitivity to impairment in unaffected relatives and the pattern of aggregation in families remain unexplored. To our knowledge, only one study reported relatives-controls differences on MCCB tests (Lopez-Garcia *et al.* 2013), including <50 unaffected relatives.

The first aim of the present study was to investigate cognitive impairment of a large sample of outpatients with schizophrenia and their unaffected first-degree relatives, recruited for the Italian Network for Research on Psychoses study (Galderisi *et al.* 2014, 2016). The normative sample for the standardization of the MCCB battery is representative of the Italian population and has been recruited in the same study. The second aim of the study was to explore familial aggregation of performance on MCCB domains by estimating probands' effects on MCCB scores of unaffected relatives.

Methods

Subjects

Study participants were patients, unaffected relatives, and healthy controls recruited for the Italian Network for Research on Psychosis study (Galderisi *et al.* 2014, 2016).

Specifically, 921 patients living in the community and consecutively seen at the outpatient units of 26 Italian university psychiatric clinics and/or mental health departments were enrolled if they had a diagnosis of schizophrenia confirmed with the Structured Clinical Interview for DSM-IV - Patient version (SCID-I-P) and an age between 18 and 66 years. Exclusion criteria were: (a) a history of head trauma with loss of consciousness; (b) a history of moderate-to-severe mental retardation or of neurological diseases; (c) a history of alcohol and/or substance abuse in the last 6 months; (d) current pregnancy or lactation; (e) inability to provide an informed consent; and (f) any antipsychotic treatment modifications and/or hospitalization due to symptom exacerbation in the last 3 months. The 26 study sites were grouped into three macro-areas: Northern Italy (eight centers), Southern Italy (seven centers, including the isles Sicily and Sardinia) and Central Italy (11 centers). Of the 921 recruited patients, 852 had complete demographic and neuropsychological data and were used in the present analyses.

For each recruited patient who agreed to involve relatives, two first-degree relatives were recruited, when available. They had to be, in order of preference, the two parents, or one parent and one sibling, or two siblings. Relatives were asked to participate and included in the study if they did not meet criteria for a current or lifetime psychiatric diagnosis as assessed by the SCID-I-Non Patient version and the SCID-II. Further exclusion criteria were: (a) a history of head trauma with loss of consciousness, (b) neurological disease, (c) history of alcoholism or substance abuse in the last 6 months, and (d) inability to provide informed consent.

According to the above criteria, 379 unaffected relatives (REL) were recruited. About two-thirds were parents and one-third siblings (they included 109 fathers, 150 mothers, 67 sisters, and 53 brothers). Three hundred and forty-two relatives had complete data and were utilized in the analyses. They were related to 247 probands (29.9% of the total proband sample used in the present analyses). One hundred twenty-five probands had one relative, 122 had two relatives.

Healthy subjects were recruited through flyers from the community at the same sites as the patient sample, using a stratified design by age, gender, and education within geographical macroareas. They were included if: (1) they had a negative family history of mood or psychotic disorders; (2) they did not meet criteria for a current or lifetime psychiatric diagnosis as assessed by the SCID-I-Non Patient version and the SCID-II, as well as other exclusion criteria listed for the relatives.

Each macro-area had to contribute at least 200 control subjects (maximum 333). As to age, controls were drawn from three groups: 18–39, 40–49, and 50–59 years. Because age-related changes in cognition are typically small for persons in their 20s and 30s (Kern *et al.* 2008), these two decades were treated as a single age group. As to education, controls were stratified according to three groups: less than a high school degree, high school degree but less than a bachelor's degree, and a bachelor's degree or higher.

According to the above criteria, 780 subjects were recruited. Two hundred and seventy-eight were from Northern Italy, 241 from Southern Italy, and 261 from Central Italy. Females were 402 (51.5%) and males were 378 (48.5%); N = 323 (41.4%) were aged 20–39 years, N = 213 (27.3%) 40–49 years, and N = 244 (31.3%) 50–59 years. Concerning education, 279 (35.8%) had less than a high school degree, 340 (43.6%) had a high school degree but less than a college degree, and 161 (20.6%) had at least a bachelor's degree. In the present analyses, only subjects with complete demographic and neuropsychological data were utilized (N = 774).

Procedures

All subjects provided written informed consent to participate after receiving a comprehensive explanation of the study procedures and goals.

The study has been conducted in accordance with the principles of the Declaration of Helsinki (59th World Medical Association General Assembly; October 2008). Approval of the study protocol was obtained from the Ethics Committees of the participating centers.

Assessments

Enrolled subjects completed the relevant assessments for the study in 2 days with the following schedule: collection of sociodemographic information and diagnostic interviews on day 1, in the morning; assessment of cognition on day 2, in the morning, to control for time-of-day effects on cognitive performance. The full study procedure has been reported elsewhere (Galderisi *et al.* 2014, 2016).

Neurocognitive functions were evaluated using the MCCB (Kern *et al.* 2008; Nuechterlein *et al.* 2008). Briefly, the MCCB includes 10 neuropsychological tests (Category Fluency – Animal Naming; Brief Assessment of Cognition in Schizophrenia Symbol Coding; Trail Making Test – Part A; Continuous Performance Test – Identical Pairs; Wechsler Memory Scale Spatial Span; Letter-Number Span; Hopkins Verbal Learning Test – Revised; Brief Visuospatial Memory Test – Revised; Neuropsychological Assessment Battery – Mazes; Mayer-Salovey-Caruso Emotional Intelligence Test), and investigates seven cognitive domains (Speed of processing; Attention/vigilance; Working memory; Verbal learning; Visual learning; Reasoning and problem solving; and Social cognition). The 10 MCCB tests were administered in the order established by Kern *et al.* (2008).

Data analysis

Co-norming and standardization of the Italian MCCB test scores was carried out as described in Kern *et al.* (2008). Raw scores on

the MCCB were standardized to T-scores based on the Italian normative sample of community participants.

For cognitive domains including more than one measure, that is, Working memory and Speed of processing, the summary score for the domain was calculated by summing the T-scores of the tests included in that domain and then standardizing the sum to a T-score. The same standardization procedure was adopted for the Neurocognitive and Overall composite scores: the six (for neurocognitive) or seven (for overall composite) domain T-scores were summed, and the composite score was calculated by standardizing the sum to a T-score based on the community sample.

In this way, all test scores, domain scores, and the composite scores were standardized to the same measurement scale with a mean of 50 and s.D. of 10.

The relationship between unadjusted cognitive T-scores and demographic characteristics (gender, age, and education) in the normative sample was analyzed using multivariate analysis of variance (MANOVA).

MCCB domains T-scores adjusted for age, gender, and education were compared between the study groups using MANOVA.

Two analyses of variance (ANOVAs) were conducted to compare the Neurocognitive composite and the Overall composite corrected T-scores between groups. *Post hoc* Tamhane tests were conducted following significant MANOVA and ANOVA *F*-tests at the corrected significance level of p < 0.017 (0.05/3).

Weighted least-square regression models were used to predict relatives' unadjusted cognitive T-scores from probands' T-scores. Models were fit for each cognitive scale, the two domains including more than a single test (Processing speed and Working memory) and for the two composite scores. These analyses were weighted for the number of family members of the proband and were adjusted for relatives' gender, age, and relationship with the patient (parent/sibling).

All analyses were performed using IBM SPSS, version 20.0.

Results

Demographic correlates of cognitive functioning in the normative Italian sample

Uncorrected T-scores for the seven cognitive domains were significantly associated with age, education, and gender in the normative sample (see online Supplementary Figs S1–S3). As expected, neurocognitive performance declined significantly with age on all domains. Social cognition had a decline from the youngest age group (20–39) to the middle one, and then did not show further decline (see online Supplementary Fig. S1). The higher the education level, the better the performance across the three education groups for all neurocognitive domains, while Social cognition was significantly better for the two high-education groups v. the lowest one. Males performed better than females on Attention/vigilance, Working memory, Reasoning and problem solving, and the Neurocognitive composite, while females outperformed males on the Social cognition test (see online Supplementary Fig. S3).

Cognitive profile of patients and relatives

Participant characteristics and summary T-scores corrected for age, gender, and education for the MCCB tests are shown in

Table 1. Demographic characteristics and MCCB scores in the study groups

	Group							
	Healthy controls (<i>N</i> = 774)	Unaffected relatives (<i>N</i> = 342)	Patients with schizophrenia (<i>N</i> = 852)					
	N (%)	N (%)	N (%)					
Gender								
Females	400 (51.7%)	197 (57.6%)	258 (30.3%)					
Males	374 (48.3%)	145 (42.4%)	594 (69.7%)					
	Mean ± s.p.	Mean ± s.p.	Mean ± s.d.					
Age (years)	40.5 ± 12.5	53.9 ± 13.5	39.8 ± 10.6					
Education (years)	13 ± 4	11.5 ± 3.9	11.8 ± 3.4					
MCCB scores								
TMT	50.1 ± 9.8	46.2 ± 11.6	35.5 ± 12.4					
BACS-SC	50.1 ± 10.0	47.0 ± 8.4	36.3 ± 8.4					
HVLT-R	50 ± 9.9	48.0 ± 11.2	35.6 ± 11.7					
WMS-III SS	50 ± 10	47.0 ± 10.2	38.0 ± 11.1					
LNS	50 ± 10	48.1 ± 10.5	37.5 ± 11.2					
NAB Mazes	50.1 ± 10	47.6 ± 10.8	38.0 ± 10.2					
BVMT-R	50.1 ± 10	46.6 ± 12.2	32.2 ± 14.7					
Fluency	50 ± 10	47.4 ± 9.6	32.7 ± 14.6					
CPT-IP	50.1 ± 10	46.7 ± 10.2	37.3 ± 11.3					
MSCEIT	50 ± 10	50.1 ± 10.4	42.3 ± 11.4					
Neurocog comp	50.1 ± 9.9	45.6 ± 11.2	28.7 ± 12.1					
Overall composite	50.1 ± 9.9	46.0 ± 11.1	28.7 ± 12.0					

MCCB, MATRICS Consensus Cognitive Battery; TMT, Trail Making Test-Part A; BACS-SC, Brief Assessment of Cognition in Schizophrenia Symbol Coding; HVLT-R, Hopkins Verbal Learning Test-Revised; WMS-III SS, Wechsler Memory Scale Spatial Span; LNS, Letter-Number Span; NAB Mazes, Neuropsychological Assessment Battery-Mazes; BVMT-R, Brief Visuospatial Memory Test-Revised; Fluency, Category Fluency-Animal Naming; CPT-IP, Continuous Performance Test-Identical Pairs; MSCEIT, Mayer-Salovey-Caruso Emotional Intelligence Test; Neurocog Comp, Neurocognitive composite.

Table 1 (participants with complete data only). Patients scored 1–2 s.D. below the normative sample, and relatives scored about 0.5 s.D. below the normative sample. The MANOVA showed a significant group effect (F = 87.4, df = 12,3974, p < 0.01). Post hoc pairwise comparisons showed that patients and relatives differed from controls and from each other on all domains, while on Social cognition patients differed from the two other groups, but relatives did not differ from controls (Fig. 1). ANOVAs for the Neurocognitive and the Overall composite showed a large effect of group (F = 798.4, df = 2,1963, p < 0.001; F = 812.3, df = 2,1963, p < 0.001; All post hoc comparisons were significant at p < 0.017 (Fig. 1).

Family aggregation of cognitive deficits as assessed by the

Table 2 shows the results of weighted least-square regression models for the MCCB tests/domains and composite scores. In the unadjusted models, including only the proband score as the independent variable, all proband scores predicted significantly the relatives' scores, except for Visual learning and Working memory. However, after adjusting for relatives' gender, age, and relationship with the proband (parent/sibling), all relatives' scores were predicted by probands' scores, except for visual learning.

Verbal learning scores had the strongest association between patients and relatives (adj $\beta = 0.237$), followed by MSCEIT (adj $\beta = 0.230$), Speed of processing (adj $\beta = 0.208$), Reasoning and problem solving (adj $\beta = 0.196$), Working memory (adj $\beta = 0.159$) and Attention/vigilance (adj $\beta = 0.116$). For those models showing a significant effect of proband scores, the variance explained in the relative scores was relatively modest, and ranged from 0.2% for Attention/vigilance to 5.8% for MSCEIT. The relative Overall and Neurocognitive composite scores were also significantly associated with proband scores (adj $\beta = 0.224$ and 0.187, respectively; variance explained =4.6% and 3.3%, respectively).

Discussion

МССВ

In line with previous investigations, data from this standardization sample demonstrated significant age, gender, and education effects on the MCCB domains (Kern et al. 2008; Mohn et al. 2012; Rodriguez-Jimenez et al. 2015). As expected, age had a linear detrimental effect on cognitive performance for all domains, with older age groups performing worse than younger ones, except for the Social cognition domain, for which the two oldest groups did not differ. Education showed a positive effect on the MCCB scores of healthy adults, with better performance associated with higher education. The gender effects observed in our standardization sample confirmed those found in the original study by Kern et al. (2008), showing that males had a better performance than females on all domains except on learning. Our findings demonstrated that females outperformed males on Social cognition. These latter findings are in general agreement with results obtained with MCCB (Mohn et al. 2012) and with other test batteries in healthy subjects (Roalf et al. 2014; Gur & Gur, 2016).

Using the Italian version of the MCCB, we confirmed the profile of cognitive impairment reported by several independent groups in a large cohort of stabilized chronic outpatients with schizophrenia (Kern *et al.* 2008, 2011; Keefe *et al.* 2011; Shamsi *et al.* 2011; Lystad *et al.* 2014; McCleery *et al.* 2014; Rodriguez-Jimenez *et al.* 2015): on average, patients scored 1–2 s.D. below controls on all domains and on the composite scores.

In our study, unaffected relatives had intermediate scores with respect to patients and controls on the MCCB neurocognitive domains. Thus, in line with a previous small study (Lopez-Garcia *et al.* 2013), our findings demonstrate that the MCCB is suitable to explore impairment in non-psychotic relatives of patients with schizophrenia. Our findings, in line with other recent evidence (Schulze-Rauschenbach *et al.* 2015; Hochberger *et al.* 2016), support the presence of deficits across multiple domains in unaffected first-degree relatives of patients with schizophrenia.



Fig. 1. Neurocognitive profile of patients with schizophrenia and their unaffected relatives on the MATRICS Consensus Cognitive Battery (MCCB). T-scores standardized to the Italian normative sample (mean 50 and s.p. 10) are reported, with correction for age, gender, and education effects. All pairwise comparisons (patients v. controls, relatives v. controls, and patients v. relatives) are statistically significant (*post hoc* Tamhane test p < 0.017, controlled for multiple comparisons), except for Social cognition, for which patients differed from controls and relatives, but the latter group did not differ from controls.

Table 2. Weighted least-square regression estimates of the association between proband and unaffected relatives scores on the MATRICS Consensus C	cognitive
Battery (MCCB) individual tests and domains (separately reported only for the two domains which include more than one test) and composite scores	

MCCB test (domain)	Unadj. stand. β	p	r² (%)	Adj. stand.* β	p	r² (%)
Trail Making Test (Speed of Processing)	0.169	<0.001	3.6	1.373	<0.001	1.9
BACS-Symbol Coding (Speed of Processing)	0.238	<0.001	5.2	0.199	<0.001	3.4
Category Fluency (Speed of Processing)	0.147	0.010	1.6	0.138	0.013	1.3
Hopkins Verbal Learning Test-Revised (Verbal learning)	0.267	<0.001	7.2	0.237	<0.001	5.3
Brief Visuospatial memory Test-Revised (Visual learning)	0.088	0.079	0.6	-	-	-
WSM-Spatial Span (Working memory)	0.219	<0.001	5.4	0.184	<0.001	3.2
Letter Number Span (Working memory)	0.093	0.055	0.8	-	-	-
NAB-Mazes (Reasoning and problem solving)	0.214	<0.001	3.8	0.196	<0.001	3.0
CPT-Identical Pairs (Attention/vigilance)	0.131	0.012	1.6	0.116	0.010	0.2
MSCEIT Managing Emotions (Social cognition)	0.247	<0.001	7.1	0.23	<0.001	5.8
MCCB Domains and composite scores						
Speed of processing	0.247	<0.001	6.2	0.208	< 0.001	4.6
Working memory	0.173	<0.001	3.2	0.159	<0.001	2.2
Neurocognitive composite	0.213	<0.001	4.3	0.187	< 0.001	3.3
Overall composite	0.247	< 0.001	6.1	0.224	< 0.001	4.7

Adj., adjusted; Unadj., unadjusted; stand., standardized; *adjusted for relatives' gender, age, and relationship with the proband (parent/sibling) and weighted for the number of relatives. BACS, Brief Assessment of Cognition in Schizophrenia; WSM, Wechsler Memory Scale-Third Edition; NAB, Neuropsychological Assessment Battery; CPT, Continuous Performance Test.

The effect size of the impairment in relatives found in our study, ranging from small to medium (0.23–0.46), is comparable with what has been reported by several other studies focusing on neurocognitive functions (Sitskoorn *et al.* 2004; Szöke *et al.* 2005; Snitz *et al.* 2006; Trandafir *et al.* 2006; Schulze-Rauschenbach *et al.* 2015). Working memory, Speed of processing, Attention

and Spatial memory were the most impaired, while Verbal memory and Problem solving the least impaired. While there is a general agreement on the neurocognitive domains found impaired in relatives, the effect size for each domain was found to vary (Snitz *et al.* 2006; Trandafir *et al.* 2006; Gur *et al.* 2007; Schulze-Rauschenbach *et al.* 2015). Possible reasons for the discrepancies seem to be the type of relatives included in different studies (young sibling/offspring are generally found more impaired than older parents), age- and education-matching between relatives and controls (unmatched sample present the greatest difference) and the exclusion criteria, in particular, the exclusion of Axis II diagnoses in relatives (Snitz *et al.* 2006; Gur *et al.* 2007; Calkins *et al.* 2013; Schulze-Rauschenbach *et al.* 2015). In our study, the relatives were mostly parents, whose age at testing was beyond the schizophrenia maximum age risk, without any Axis I or II diagnosis, and we compared age- and education-corrected scores.

The only domain that did not show an impairment in relatives in our study was Social cognition. Literature findings for this domain have been mixed, ranging from a mild-to-moderate impairment to no deficit (Eack *et al.* 2010; Fett *et al.* 2013; Kohler *et al.* 2014; Ruocco *et al.* 2014; Gur & Gur, 2016). The use of heterogeneous measures of Social cognition, the age of included subjects, the presence of prodromal symptoms or Axis I or II diagnoses are again the main factors involved in the heterogeneity of findings (Kohler *et al.* 2014; Gur & Gur, 2016).

Our study is the first one to investigate aggregation in families of the MCCB scores. With the exception of Spatial memory, all MCCB domain scores were significantly predicted by the corresponding proband scores. The effect size was larger for Social cognition, Verbal memory, Speed of processing (in particular for the Symbol Coding test), Working memory, in particular the Spatial Span, and Reasoning and problem solving (as assessed by the Mazes test), while the Attention/vigilance domain had the least effect size. These results are in general agreement with those reported by Calkins et al. (2013), using the Penn Computerized Neurocognitive Battery (CNB), except for Verbal memory, which in their study was not found to be predicted by proband scores. The discrepancy concerning the prediction of this domain might be due to methodological factors or to different liability to schizophrenia within the samples included in the two studies. As to methodological factors, Verbal memory in Calkins et al.'s study was assessed only for a subsample of subjects and was found to be intact in relatives, at odds with our and other findings (Sitskoorn et al. 2004; Szöke et al. 2005; Snitz et al. 2006; Trandafir et al. 2006; Schulze-Rauschenbach et al. 2015; Hou et al. 2016). It is also possible that some of the relatives have less unexpressed liability to schizophrenia and might present with less Verbal memory impairment. Future studies could clarify whether the pattern of impairment in relatives of patients with schizophrenia is related to the degree of unexpressed liability to schizophrenia.

A general problem with the family study literature is the use of many different measures of neuropsychological performance. The use of MCCB might help to standardize the use of cognitive tests and domains in schizophrenia family studies. Social cognition, as assessed by the MSCEIT, was not impaired in our sample of unaffected first-degree relatives. However, proband scores significantly predicted relative scores, and explained 5.8% of the latter scores variance. Apart from the Calkins *et al.* study, including a simple facial emotion recognition task, to our knowledge, there is no other study investigating familial aggregation of deficit on this domain.

An unresolved issue is whether the observed aggregations are specific to schizophrenia or reflect the transmission of cognitive abilities in families. Only studies including relatives of patients and of healthy subjects might clarify the latter issue.

In conclusion, in a large sample of stabilized patients with schizophrenia, living in the community, and in their unaffected relatives, MCCB demonstrated sensitivity to cognitive deficits in both groups. Our findings of significant within-family prediction of MCCB scores might suggest an influence of disease-related genetic and environmental factors on several cognitive domains, including social cognition. As recently reported in a meta-analysis of twin and family-based heritability studies (Blokland *et al.* 2017), in subjects with schizophrenia cognitive dysfunctions and liability to the disorder have partially shared genetic etiology. However, schizophrenia has a complex, polygenic etiology (involving many genes with small effect sizes), and it is increasingly acknowledged that gene x environment interactions, epigenetically regulated gene expression, and environmental factors have an essential contributing role in its liability (Braff & Tamminga, 2017).

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0033291717002902.

Acknowledgements. The study was funded by the Italian Ministry of Education (grant number: 2010XP2XR4), the Italian Society of Psychopathology (SOPSI), the Italian Society of Biological Psychiatry (SIPB), Roche, Lilly, AstraZeneca, Lundbeck, and Bristol-Myers Squibb.

Declaration of Interest. The authors have declared that there are no conflicts of interest in relation to the subject of this study.

Ethical Standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

References

- Blokland GA, et al. (2017) Heritability of neuropsychological measures in schizophrenia and nonpsychiatric populations: a systematic review and meta-analysis. *Schizophrenia Bulletin* **43**, 788–800.
- **Bora E, et al.** (2014) Cognitive deficits in youth with familial and clinical high risk to psychosis: a systematic review and meta-analysis. *Acta Psychiatrica Scandinavica* **130**, 1–15.
- Bora E and Pantelis C (2013) Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis. *Schizophrenia Research* 144, 31–36.
- Bowie CR, *et al.* (2006) Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. *American Journal of Psychiatry* **163**, 418–425.
- Braff DL and Tamminga CA (2017) Endophenotypes, epigenetics, polygenicity and more: Irv Gottesman's Dynamic Legacy. *Schizophrenia Bulletin* 43, 10–16.
- Brahmbhatt SB, et al. (2006) Neural correlates of verbal and nonverbal working memory deficits in individuals with schizophrenia and their high-risk siblings. Schizophrenia Research 87, 191–204.
- Calkins ME, et al. (2013) Sex differences in familiality effects on neurocognitive performance in schizophrenia. Biological Psychiatry 73, 976–984.
- Calkins ME, et al. (2010) Project among African-Americans to explore risks for schizophrenia (PAARTNERS): evidence for impairment and heritability of neurocognitive functioning in families of schizophrenia patients. *American Journal of Psychiatry* 167, 459–472.
- Chen LS, et al. (2009) Familial aggregation of clinical and neurocognitive features in sibling pairs with and without schizophrenia. Schizophrenia Research 111, 159–166.
- Chen WJ, et al. (1998) Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. American Journal of Psychiatry 155, 1214–1220.
- Couture SM, Granholm EL and Fish SC (2011) A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and

real-world functioning in schizophrenia. *Schizophrenia Research* **125**, 152–160.

- de Achával D, et al. (2010) Emotion processing and theory of mind in schizophrenia patients and their unaffected first-degree relatives. *Neuropsychologia* 48, 1209–1215.
- Dickerson F, et al. (2014) A longitudinal study of cognitive functioning in schizophrenia: clinical and biological predictors. *Schizophrenia Research* 156, 248–253.
- Eack SM, et al. (2010) Social cognition deficits among individuals at familial high risk for schizophrenia. *Schizophrenia Bulletin* **36**, 1081–1088.
- Fett AK, Maat A and GROUP Investigators (2013) Social cognitive impairments and psychotic symptoms: what is the nature of their association? *Schizophrenia Bulletin* **39**, 77–85.
- Fett AK, et al. (2011) The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. *Neuroscience and Biobehavioral Reviews* **35**, 573–588.
- Galderisi S, et al. (2013) Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. *Schizophrenia Research* 147, 157–162.
- Galderisi S, et al. (2009) Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. *Schizophrenia Research* 115, 104–114.
- Galderisi S, et al. (2002) Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. *American Journal of Psychiatry* 159, 983–990.
- Galderisi S, et al. (2014) The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry 13, 275–287.
- Galderisi S, et al. (2016) Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. *Schizophrenia Research* 175, 154–160.
- Gallagher S and Varga S (2015) Social cognition and psychopathology; a critical overview. World Psychiatry 14, 5–14.
- Green MF (2016) Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. *Journal of Clinical Psychiatry* 77(Suppl. 2), 8–11.
- Green MF, et al. (2012a). Social cognition in schizophrenia, part 1: performance across phase of illness. *Schizophrenia Bulletin* **38**, 854–864.
- Green MF, Harris JG and Nuechterlein KH (2014) The MATRICS consensus cognitive battery: what we know 6 years later. *American Journal of Psychiatry* 171, 1151–1154.
- Green MF, et al. (2012b). From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Archives of General Psychiatry 69, 1216–1224.
- Green MF, et al. (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? *Schizophrenia Bulletin* **26**, 119–136.
- Green MF, Kern RS and Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. *Schizophrenia Research* 72, 41–51.
- Green MF, et al. (2008) Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. *Schizophrenia Bulletin* **34**, 1211–1220.
- Grove WM, et al. (1991) Familial prevalence and coaggregation of schizotypy indicators: a multitrait family study. *Journal of Abnormal Psychology* 100, 115–121.
- Gur RC and Gur RE (2016) Social cognition as an RDoC domain. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 171B, 132– 141.
- Gur RE, et al. (2007) Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia. American Journal of Psychiatry 164, 813–819.
- Harvey PD and Strassnig M (2012) Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. *World Psychiatry* **11**, 73–79.
- Heinrichs RW and Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology* **12**, 426–445.

- Hochberger WC, et al. (2016) Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. *Schizophrenia Research* **170**, 156–161.
- Hou CL, *et al.* (2016) Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. *Schizophrenia Research* **174**, 71–76.
- Keefe RS, et al. (2011) Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophrenia Research 125, 161–168.
- Kern RS, et al. (2011) The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophrenia Research 126, 124–131.
- Kern RS, et al. (2008) The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. American Journal of Psychiatry 165, 214–220.
- Kohler CG, et al. (2014) Facial emotion perception differs in young persons at genetic and clinical high-risk for psychosis. Psychiatry Research 216, 206– 212.
- Kohler CG, et al. (2010) Facial emotion perception in schizophrenia: a meta-analytic review. Schizophrenia Bulletin 36, 1009–1019.
- Kurtz MM, Jeffrey SB and Rose J (2010) Elementary neurocognitive function, learning potential and everyday life skills in schizophrenia: what is their relationship? *Schizophrenia Research* 116, 280–288.
- Lavoie MA, et al. (2013) Social cognition in first-degree relatives of people with schizophrenia: a meta-analysis. Psychiatry Research 209, 129–135.
- Leifker FR, Bowie CR and Harvey PD (2009) Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. *Schizophrenia Research* 115, 82–87.
- Lopez-Garcia P, et al. (2013) Impact of COMT genotype on cognition in schizophrenia spectrum patients and their relatives. *Psychiatry Research* 208, 118–124.
- Lystad JU, et al. (2014) The MATRICS consensus cognitive battery (MCCB): performance and functional correlates. *Psychiatry Research* 220, 1094–1101.
- Mancuso F, et al. (2011) Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome. *Schizophrenia Research* **125**, 143–151.
- McCleery A, et al. (2014) Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) profile of impairment. Schizophrenia Research 157, 33–39.
- Mohn C, Sundet K and Rund BR (2012) The Norwegian standardization of the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery. Journal of Clinical and Experimental Neuropsychology 34, 667–677.
- Nuechterlein KH, et al. (2008) The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. American Journal of Psychiatry 165, 203–213.
- Roalf DR, et al. (2014) Within-individual variability in neurocognitive performance: age- and sex-related differences in children and youths from ages 8 to 21. Neuropsychology 28, 506–518.
- Rodriguez-Jimenez R, et al. (2015) The MCCB impairment profile in a Spanish sample of patients with schizophrenia: effects of diagnosis, age, and gender on cognitive functioning. Schizophrenia Research 169, 116–120.
- **Ruocco AC, et al.** (2014) Emotion recognition deficits in schizophrenia-spectrum disorders and psychotic bipolar disorder: findings from the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) study. *Schizophrenia Research* **158**, 105–112.
- Schmidt SJ, Mueller DR and Roder V (2011) Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. *Schizophrenia Bulletin* 37(Suppl. 2), S41–S54.
- Schulze-Rauschenbach S, et al. (2015) Neurocognitive functioning in parents of schizophrenia patients: attentional and executive performance vary with genetic loading. *Psychiatry Research* 230, 885–891.
- Seidman LJ, et al. (2015) Factor structure and heritability of endophenotypes in schizophrenia: findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophrenia Research 163, 73–79.
- Shamsi S, et al. (2011) Cognitive and symptomatic predictors of functional disability in schizophrenia. *Schizophrenia Research* **126**, 257–264.

- Sitskoorn MM, et al. (2004) Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. *Schizophrenia Research* 71, 285–295.
- Snitz BE, Macdonald III AW and Carter CS (2006) Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. *Schizophrenia Bulletin* 32, 179–194.
- Szöke A, et al. (2005) Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysis. *Psychological Medicine* 35, 771–782.
- Trandafir A, et al. (2006) Memory tests in first-degree adult relatives of schizophrenic patients: a meta-analysis. Schizophrenia Research 81, 217–226.

Appendix

Members of the Italian Network for Research on Psychoses participating in this study include: Giuseppe Piegari, Annarita Vignapiano, Federica Caputo, Giuseppe Plescia, Valentina Montefusco (Campania University "Luigi Vanvitelli"); Marina Mancini, Maria Teresa Attrotto, Vittoria Paladini (University of Bari); Anna Rita Atti (University of Bologna); Stefano Barlati,

Alessandro Galluzzo, Christian Mussoni (University of Brescia); Federica Pinna, Lucia Sanna, Diego Primavera (University of Cagliari); Maria Salvina Signorelli, Giuseppe Minutolo, Dario Cannavò (University of Catania); Tiziano Acciavatti, Rita Santacroce, Mariangela Corbo (University of Chieti); Mario Altamura, Maddalena La Montagna, Raffaella Carnevale (University of Foggia); Giulia Pizziconi, Rodolfo Rossi, Valeria Santarelli, Laura Giusti, Maurizio Malavolta, Anna Salza (University of L'Aquila); Martino Belvederi Murri, Pietro Calcagno, Michele Bugliani (University of Genoa); Marta Serati, Giulia Orsenigo (University of Milan); Carla Gramaglia, Eleonora Gattoni, Carlo Cattaneo (University of Eastern Piedmont, Novara); Nadia Campagnola, Luisa Ferronato, Cristiano Piovan (University of Padua); Matteo Tonna, Elena Bettini, Paolo Ossola (University of Parma); Camilla Gesi, Paola Landi, Grazia Rutigliano (University of Pisa); Massimo Biondi, Paolo Girardi, Antonino Buzzanca, Monica Zocconali, Anna Comparelli, Igina Mancinelli (Sapienza University of Rome); Cinzia Niolu, Michele Ribolsi, Alberto Siracusano (Tor Vergata University of Rome); Giulio Corrivetti, Luca Bartoli, Ferdinando Diasco (Department of Mental Health, Salerno); Simone Bolognesi, Arianna Goracci, Andrea Fagiolini (University of Siena); Silvio Bellino, Simona Cardillo, Nadja Bracale (University of Turin).